Currently out of the existing stock ratings of Yasmeen Rahimi, 281 are a BUY (96.23%), 11 are a HOLD (3.77%).

Yasmeen Rahimi

Work Performance Price Targets & Ratings Chart

Analyst Yasmeen Rahimi, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 36.03% that have a potential upside of 45.76% achieved within 193 days.

Yasmeen Rahimi’s has documented 569 price targets and ratings displayed on 54 stocks. The coverage is on Healthcare, Industrials, Technology sectors.

Most recent stock forecast was given on KRRO, Frequency Therapeutics at 13-Nov-2025.

Wall Street Analyst Yasmeen Rahimi

Analyst best performing recommendations are on KRRO (FREQUENCY THERAPEUTICS).
The best stock recommendation documented was for KRRO (FREQUENCY THERAPEUTICS) at 11/13/2025. The price target of $11 was fulfilled within 1 day with a profit of $20.42 (64.99%) receiving and performance score of 649.9.

Average potential price target upside

ALBO Albireo Pharma ALGS Aligos Therapeutics  ALT Altimmune AMRN Amarin PLC ARCT Arcturus Therapeutics Holdings CBAY Cymabay Therapeu ENTA Enanta Pharmaceuticals ETN Eaton PLC ICPT Intercept Pharmaceuticals IMUX Immunic LMNL Liminal BioSciences MDGL Madrigal Pharmaceuticals MIRM Mirum Pharmaceuticals MRNA Moderna MTNB Matinas BioPharma Holdings NGM NGM Biopharmaceuticals PTGX Protagonist Therapeutics RPHM Reneo Pharmaceuticals SAGE Sage Therapeutic VTYX Ventyx Biosciences VXRT Vaxart ALNA Allena Pharmaceuticals CYTK Cytokinetics LUMO Lumos Pharma PLRX Pliant Therapeutics  AKUS Akouos  DSGN Design Therapeutics RXDX Prometheus Biosciences TNYA Tenaya Therapeutics PRAX Praxis Precision Medicines  CINC CinCor Pharma GOSS Gossamer Bio LXRX Lexicon Pharmaceuticals AXLA Axcella Health GALT Galectin Therapeutics GEMP Gemphire Therapeutics LOGC LogicBio Therapeutics NRBO Neurobo Pharmaceuticals PRTA Prothena plc SVRA Savara IMVT Immunovant  SLNO Soleno Therapeutics CRNX Crinetics Pharmaceuticals EWTX Edgewise Therapeutics VRNS Varonis Systems GPCR Structure Therapeutics American Depositary Shares KRRO Frequency Therapeutics NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares SLRN ACELYRIN, INC. Common Stock CNAT Conatus Pharmaceuticals LRMR Larimar Therapeutics MDCO The Medicines Company VRNA Verona Pharma PLC ADR ZFGN Zafgen

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$42

$-2.15 (-4.87%)

$42

2 years 10 months 12 days ago
(15-Feb-2023)

0/15 (0%)

$-2.18 (-4.93%)

Buy

$42

$-2.15 (-4.87%)

$82

2 years 11 months 16 days ago
(11-Jan-2023)

0/4 (0%)

$-2.1 (-4.76%)

Buy

$42

$-2.15 (-4.87%)

$68

2 years 11 months 16 days ago
(11-Jan-2023)

0/3 (0%)

$-2.1 (-4.76%)

Hold

$55

2 years 11 months 16 days ago
(11-Jan-2023)

0/1 (0%)

$36.77 (201.70%)

Hold

$42

$-2.15 (-4.87%)

$61

2 years 11 months 18 days ago
(09-Jan-2023)

0/2 (0%)

$-1.85 (-4.22%)

Show more analysts

Please expand the browser size to see the chart

Which stock is Yasmeen Rahimi is most bullish on?

Potential upside of $65.2 has been obtained for ARCT (ARCTURUS THERAPEUTICS HOLDINGS)

Which stock is Yasmeen Rahimi is most reserved on?

Potential downside of -$56.98 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

What Year was the first public recommendation made by Yasmeen Rahimi?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?